Preclinical
While some may wonder about the commercial future of these late-to-the-market solutions, the developers themselves are taking a long view.
BlueSphere Bio aims to overcome challenges in the CAR T space with a precision approach to T cell therapy.
Nuravax is developing an Alzheimer’s vaccine to induce therapeutically potent concentrations of antibodies against pathological proteins. Know more here.
While it has yet to reach clinical trials, preclinical results with the company’s specially-tailored adeno-associated virus have been fortuitously auspicious.
The patch is not only painless, it requires less vaccine to generate the same or greater effects.
Unlike most companies addressing the diseases associated with aging, Rejuvenate Bio tackles multiple cardiac, metabolic and renal issues at once.
Sage Therapeutics and Biogen announced positive results from their ongoing clinical trials on the efficacy and safety of zuranolone in treating major depressive disorder and postpartum depression.
The ability to utilize one protein degrader against a whole host of diseases drives Kymera’s strategy when choosing protein targets.
Pfizer reported three cases of muscle weakness, two of which involved inflammation of the heart (myocarditis).
Monoclonal antibodies play a key role in the treatment of COVID-19, but new research suggests that nanobodies derived from llamas could provide an alternative to monoclonal antibodies.
PRESS RELEASES